REVIEW ARTICLE

SATB2: A versatile transcriptional regulator of craniofacial and skeleton development, neurogenesis and tumorigenesis, and its applications in regenerative medicine

Xia Huang a,b, Qiuman Chen a,b, Wenping Luo a,b,c, Mikhail Pakvasa c,d,e, Yuxin Zhang a,b, Liwen Zheng a,b, Shuang Li a,b, Zhuohui Yang a,b, Huan Zeng a,b, Fang Liang a,b, Fugui Zhang a,b,c, Daniel A. Hu c, Kevin H. Qin c, Eric J. Wang c, David S. Qin c, Russell R. Reid c,e, Tong-Chuan He c,e, Aravind Athiviraham c, Mostafa El Dafrawy c, Hongmei Zhang a,c,f,*

a Stomatological Hospital of Chongqing Medical University, Chongqing 401147, PR China
b Chongqing Key Laboratory of Oral Diseases and Biomedical Sciences, Chongqing 401147, PR China
c Molecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA
d The Pritzker School of Medicine, The University of Chicago Medical Center, Chicago, IL 60637, USA
e Department of Surgery, The University of Chicago Medical Center, Chicago, IL 60637, USA
f Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing 401147, PR China

Received 30 June 2020; received in revised form 30 August 2020; accepted 6 October 2020
Available online 17 October 2020

Abstract SATB2 (special AT-rich sequence-binding protein 2) is a member of the special AT-rich binding protein family. As a transcription regulator, SATB2 mainly integrates higher-order chromatin organization. SATB2 expression appears to be tissue- and stage-specific, and is governed by several cellular signaling molecules and mediators. Expressed in branchial arches and osteoblast-lineage cells, SATB2 plays a significant role in craniofacial pattern and skeleton development. In addition to regulating osteogenic differentiation, SATB2 also displays versatile functions in neural development and cancer progression. As an osteoinductive factor, SATB2

Keywords Bone regeneration; Development; Neurogenesis; SATB2; Tumorigenesis

* Corresponding author. Stomatological Hospital of Chongqing Medical University, Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing 401147, PR China. Fax: +86 23 8886 0222.
E-mail address: hmzhang@hospital.cqmu.edu.cn (H. Zhang).
Peer review under responsibility of Chongqing Medical University.

https://doi.org/10.1016/j.gendis.2020.10.003
2352-3042/© 2020, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Fractures and bone defects are common and complicated clinical problems that pose a great challenge for the healthcare system and place a huge burden on the affected patients. At present, the most widely used substitute materials for bone reconstruction include autologous bone, allogeneic bone and synthetic bone. Autologous and allogeneic bone grafts may increase donor site morbidity and have the potential risk of disease transmission, respectively. On the other hand, the osteogenic capacity of the synthesized bone substitute materials are not as effective as those of autologous and allogeneic bone grafts. Thus, bone tissue engineering is a promising therapeutic strategy to promote regeneration of bone tissue and repair bone defects. A biological factor that effectively stimulates osteogenic differentiation of mesenchymal stem cells (MSCs) is one of the most important components of successful bone tissue engineering. Therefore, as a potent osteoinductive factor, SATB2 may be a potential factor for bone reconstruction.

Special AT-rich sequence-binding protein (SATB) family proteins are key regulators of gene expression that mediate higher-order chromatin organization. The SATB family members SATB1 and SATB2 share considerable sequence homology and play similar roles in transcriptional regulation as both of them are implicated in long-range enhancer function extension of chromatin modifications and dynamic tethering of chromatin loops. The human SATB2 gene is located in a gene-poor region of 2q32-q33, which was originally identified as KIAA1034, a near full-length cDNA (AB028957). The SATB2 transcript is assembled from 11 exons spanning 191 kb, and encodes a large protein consisting of 733 amino acids with a molecular weight of 82.5 kDa SATB2 shows an extraordinarily high degree of evolutionary conservation, with only three amino acid substitutions between mouse and human. SATB2 protein has 5 domains that are highly conserved with those of SATB1, including a ubiquitin-like domain (ULD), a CUT repeat-like (CUTL) domain, two CUT domains (CUT1 and CUT2) and a homeodomain (HOX) (Fig. 1). As a nuclear matrix protein, SATB2 regulates gene transcription by directly binding to the core unwinding elements of nuclear matrix-attachment regions (MARs) through the CUT1 and CUT2 domains. MARs have been identified as regulatory DNA sequences and play an important role in higher-order chromatin organization, long-range enhancer function, and extension of chromatin modifications. While binding to MARs, SATB2 can modify the chromatin structure to regulate gene expression by interacting with histone deacetylase 1 (HDAC1) and metastasis-associated protein 2 (MAT2), which are members of the nucleosome remodeling and histone deacetylase complex. Moreover, SATB2 also acts as a “scaffolding” protein that recruits other DNA-binding proteins to specific sub-nuclear sites and promotes their activities, thus participating in the regulation of gene expression.

In this review, we first present the recent findings relevant to the upstream regulators of SATB2 expression, and then explore the contribution of SATB2 to craniofacial patterning, bone formation, and neural development. Next, we summarize the roles of SATB2 in tumorigenesis and the clinical use of SATB2 as a diagnostic biomarker of cancers. Finally, we outline the potential applications of SATB2 in regenerative medicine.

Regulators of SATB2 expression and posttranslational modification

SATB2 exerts versatile functions in craniofacial patterning, osteoblast differentiation, cortical neuron differentiation and cancer initiation and progression. The diverse biological roles of SATB2 are mediated by the regulation of ligand-receptor signaling. Here, the involved regulators of SATB2 gene expression and posttranslational modification are illustrated (Fig. 2A).

Growth factors and cytokines secreted by cells

Bone morphogenetic proteins (BMPs) belong to the TGF-β superfamily, with diverse and critical biological functions including mesenchymal stem cell differentiation, bone formation, adipogenesis, angiogenesis, and metabolism. The functions of BMPs are classically mediated through the canonical BMPR-Smad-dependent pathway. Binding of BMP ligands to receptors activates receptor kinases, which leads to the phosphorylation of Smad proteins. These Smad proteins are necessary for BMP-induced osteogenic differentiation (Fig. 2A). Normal expression of BMP4 is critical for facial development; deletion or elevation of BMP4 in the cranial neural crest of mouse embryos results in severe defects of facial development. Satb2 mRNA expression was upregulated in the mandible of the mice with conditional overexpression of Bmp4 in CNC, while significantly downregulated in the mice with Bmp4 deletion in CNC, indicating that BMP4 may be an upstream regulator of SATB2. Mechanically, Smad1/5 directly binds to the conserved Smad recognition elements in the 5’ flanking region of Satb2 gene to regulate its expression.
findings suggest that SATB2 transcription is downstream of the BMP signaling pathway during facial development. Osterix (OSX), a transcription factor specifically expressed in osteoblasts, is required for osteoblast differentiation and bone formation. In Osx-null mice, no bone formation was observed although the cartilage developed normally. Tang et al found that OSX might function as an upstream regulator of SATB2 since SATB2 expression was decreased in the calvaria of Osx-null mice embryos. Knockdown of Osx expression in MC3T3 osteoblast cells by siRNA resulted in suppression of SATB2 expression. In contrast, the overexpression of Osx in the C2C12 mesenchymal cell line enhanced SATB2 expression at both mRNA and protein levels. Mechanistically, OSX can activate SATB2 expression by directly binding to the GC-rich binding sites in the proximal 130 bp of the Satb2 promoter (Fig. 2A). Taken together, the results of these studies indicate that Osx is an upstream regulator of SATB2 expression during osteoblast differentiation and bone formation.

Additionally, Apostolova et al found that SATB2 was rapidly and strongly induced by members of the neurotrophic cytokines, ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF), in postmitotic sympathetic neurons (Fig. 2A). However, the mechanism by which these two cytokines trigger SATB2 expression in neurons remains unclear.

**Protein modifiers**

The small ubiquitin-related modifier (SUMO) proteins are a family of conserved eukaryotic protein modifiers of approximately 100 amino acids. As one of the posttranslational modifications, SUMO modification has been proved to regulate the activity of transcription factors. SUMO covalently conjugates to internal lysine(s) of substrates by SUMO E1, E2, and E3 enzymes. Dobrev et al found that SUMO was conjugated to the lysine residues of the SATB2 protein with the help of SUMO E3 ligase PIAS1. The SUMO modification of SATB2 antagonizes its transcriptional activation and binding ability with MAR sequences, and influences its subnuclear localization (Fig. 2A).

**Non-coding RNA (ncRNA) molecules**

Non-coding RNA (ncRNA) molecules play diverse roles in various physiological and pathological processes by regulating target gene expression. Long non-coding RNAs (lncRNA) are transcripts that are longer than 200 nucleotides with no protein-coding capacity. LncRNA antisense transcript of SATB2 (SATB2-AS1) is an important regulator of colorectal carcinoma progression; it is expressed in normal colorectal tissues but downregulated in colorectal carcinoma. Xu et al found that lncRNA SATB2-AS1 cis-activated SATB2 transcription by recruiting WDR5 and GADD45A, and subsequently regulating DNA demethylation and H3K4me3 enrichment of the SATB2 promoter. In another study, Wang et al suggested that lncRNA SATB2-AS1 might upregulate SATB2 expression by serving as a scaffold to recruit p300, thus accelerating histone H3 acetylation at the SATB2 promoter. MicroRNAs (miRNAs) are small ncRNAs that regulate gene expression by binding to the 3' untranslated region (UTR) of target mRNAs, thereby leading to mRNA degradation or translation inhibition. Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer worldwide, and miR-211 has been shown to be an inhibitor of hepatocellular carcinoma. The expression of miR-211 has been found to be deregulated in HCC cancer tissues compared with adjacent non-neoplastic tissue. Furthermore, luciferase reporter assays have demonstrated that SATB2 is a direct target of miR-211 and SATB2 reportedly rescued the proliferation and invasion ability of HCC cells inhibited by miR-211. In fact, many other miRNAs can inhibit SATB2 expression by binding to its 3'UTR via base-pairing, including miR31, miR-34, miR-166, mi366, and mi383 (Fig. 2A). These findings strongly suggest that ncRNAs play an important role in the regulation of SATB2 expression during tumor occurrence and progression.
Nonetheless, the regulation of SATB2 expression by various cell signals in different biological processes is complicated. Only a small number of regulators have been identified. Therefore, more research is warranted to gain a better understanding of the underlying mechanisms behind the control of SATB2 expression.

**SATB2 in craniofacial development**

Craniofacial development is based on cranial neural crest (CNC) cells that migrate and aggregate at branchial arches and differentiate into multiple cell types to form specific components of the facies cranii.\(^5^3\)\(^5^7\) In mouse embryos, SATB2 expression is detected in the maxillary component of the first pharyngeal arch and the lateral aspect of the frontonasal process at E10.5.\(^6\) Then SATB2 expression demarcates the region of the medial maxillary process within the primitive oral cavity at E11--11.5. At E12.5, SATB2 expression is seen in the medial edges of the developing palatal shelves and this continues until E13.5 when the strongest expression is in the mesenchyme underlying the medial edge epithelia. At E14.5, the time of palatal shelf

---

**Figure 2** The regulative mechanism and the function of SATB2. (A) SATB2 is regulated by various cellular signaling molecules, including growth factors and cytokines secreted by cells, protein modulators and non-coding RNA molecules. (B) SATB2 plays versatile roles in craniofacial pattern and bone development, neurogenesis and tumorigenesis by regulating downstream effectors. The proteins are marked with cycles, and genes are marked with rectangles.
The physiological and pathological roles of SATB2

fusión, the SATB2 expression is dramatically downregulated.7 The functions of SATB2 in craniofacial development have been uncovered in studies of Satb2 knockout mice.18,58 Dobrev et al targeted inactivated the Satb2 gene in mouse embryonic stem (ES) cells through insertion of the bacterial β-galactosidase (LacZ) gene immediately downstream of the first ATG codon in exon 2.18 Mice carrying a mutant Satb2-LacZ allele were mated to generate heterozygous and homozygous mutant mice. Dobrev et al reported that heterozygous Satb2+/− mice were phenotypically normal and fertile, while homozygous Satb2−/− mice showed obvious craniofacial defects and died immediately after birth.18 However, in another study, Britanova et al found that Satb2 haploinsufficiency caused craniofacial abnormalities and these defects were amplified in Satb2 homozygotes.50 The discrepancy between the two studies may have been caused by differences in targeting strategies. Britanova et al constructed Satb2 deficient mice by elimination of the second exon in the protein-coding region of Satb2 gene and replacement with a Cre recombinase—coding sequence and a Neo expression cassette.38

The Satb2−/− mice showed a shorter lower jaw and were missing the anterior part of the mandible, including the incisors.18,58 Other craniofacial abnormalities were also observed in Satb2−/− mice, including microcephaly, cleft palate, and nasocapsular and premaxillary hypoplasia.18,58 Furthermore, the horns and the body of hyoid bone which are derived from the second and third branchial arches, were also malformed.18 These defects in Satb2−/− mice are similar to the phenotypes resulting from Satb2 deletions and translocations in humans.18,59 Patients with alterations in the Satb2 gene manifest with cleft palate, microcephaly, facial dysmorphic features, micrognathia, and dental anomalies.59–62 To uncover the mechanistic basis of the morphologic defects caused by Satb2 gene mutations, the expression of candidate genes that are correlated with craniofacial development were investigated in Satb2−/− mice, including Pax9, Msx1, Alx4, and Lhx7.63–73 Pax9 expression levels in the mandibular incisor field as well as those of Msx1 and Alx4 in the developing palate, were markedly decreased in Satb2−/− embryos.58 Additionally, the expression of Lhx7 was 5-fold decreased in the cells of head and branchial arch regions in Satb2−/− embryos compared to that in the wild-type.18 Both of the Pax9−/− mice and Msx1−/− mice show a cleft plate and tooth agenesis,68,74 which is also observed in Satb2−/− mice. Alx4 controls the patterning of the nose and maxillary regions,69 the abnormal nasocapsular and premaxilla in Satb2−/− embryos may owing to the decrease of Alx4. Deletion of Lhx7 in mouse embryos results in a cleft secondary palate but other craniofacial structures appear to be normal that are affected in Satb2−/− embryos.63 The changes of Pax9, Alx4, Msx1, and Lhx7 expression in Satb2−/− mutants suggest that SATB2 may play a role in craniofacial development by regulating the expression of these genes. Furthermore, Satb2−/− mice showed enhanced apoptosis in the craniofacial mesenchyme of the mandible, maxillary, and medial frontonasal process regions, where SATB2 is normally expressed in wild-type mice.58 The results indicate that SATB2 participates in craniofacial mesenchyme cell proliferation and survival, which may also provide a partial mechanistic explanation for the defects in Satb2−/− mice. Together, these data suggest that SATB2 may have a profound effect on craniofacial development by regulating gene expression associated with craniofacial development and affecting craniofacial mesenchymal cell survival.

The essential roles of SATB2 in bone and skeletal development

The function of the Satb2 gene is not restricted to the craniofacial development, in fact, later stages of Satb2−/− embryos demonstrate delayed bone formation at E15.5.18 SATB2 is expressed in the osteoblast lineage of wild-type mouse embryos, and the Satb2−/− embryos have demonstrated delayed bone formation, defective extracellular matrix deposition, and shorter and thinner trabecula as compared to those of wild-type.18 Multiple studies have indicated that SATB2 affects the expression of several key factors that regulate osteoblast differentiation.18,75–77 It appears that SATB2 acts as a molecular node of a transcriptional network regulating osteoblast differentiation and bone formation. In the following sections, we review the various factors that interact with SATB2 during bone and skeletal development.

SATB2 inhibits HOXA2-mediated suppression of osteogenic differentiation

HOXA2 is an inhibitor of bone formation and plays a role in branchial arch patterning.78 The Hoxa2−/− mice displayed abnormal craniofacial development, and ectopically activated chondrogenesis.78,79 In E15.5 Satb2−/− mice, HOXA2 expression was markedly increased in the calvarial bones and long bones.18 qPCR analysis revealed that Hoxa2 mRNA was 10 times higher in the osteoblasts isolated from Satb2−/− mice than that from the Satb2+/− group, and it was partially repressed by retrovirus-mediated SATB2 overexpression.18 These results indicate that SATB2 can inhibit HOXA2 expression in osteoblasts. Additionally, it has been shown that HOXA2 expression is self-regulated by the intragenic EII enhancer in the 3′ region of the Hoxa2 gene.60,61 Chromatin immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) experiments have revealed that SATB2 directly binds to a sequence containing the MAR element of the EII enhancer.18 Furthermore, SATB2 effectively suppressed the activity of the Hoxa2 EII enhancer. Finally, the study found that the defects of calvarial bone formation in Satb2−/− mice were largely rescued in Satb2−/− Hoxa2−/− mice, indicating that inactivation of the Hoxa2 gene can effectively overcome the bone defects caused by Satb2 deletion.18 Taken together, these results suggest that the inhibition of Hoxa2 in osteoblasts mediated by the binding of SATB2 to the EII enhancer is necessary for normal osteoblast differentiation.

SATB2 interacts with RUNX2 and forms a regulatory loop to control osteogenic differentiation

The RUNX family of transcription factors participate in cell differentiation and proliferation, bone formation, and embryonic and organ development.52–55 RUNX2 is a master regulator of osteoblast differentiation and bone formation as
targeted disruption of Runx2 in mice results in bone formation defects. Osteocalcin (OCN), a marker of osteoblast terminal differentiation, is synthesized by osteoblasts. As the most abundant non-collagenous protein in the extracellular matrix of bone, OCN is closely related to mature bone matrix mineralization. Similar to Bsp, the expression of Ocn is also regulated by Satb2. OCN protein and mRNA expression were significantly decreased by Satb2 deletion in both mouse embryos and osteoblasts. Mechanistically, over-expression of Satb2 in Satb2−/− osteoblasts enhanced the acetylation of histone H3 and the binding of RNA polymerase II in the Ocn promoter. Several studies have shown that the Ocn promoter is regulated by Runx2 and Atf4, which bind the nonadjacent sequence elements OSE2 and OSE1, respectively. It is conceivable that Satb2 may couple Atf4 and Runx2 through physical interaction to enhance their DNA binding to the Ocn promoter and then promote the expression of Ocn in an indirect fashion. Taken together, Satb2 plays a role in osteogenic differentiation partially by regulating the expression of Bsp and Ocn.

Essential roles of SATB2 in neural development
Numerous studies have focused on the spatiotemporal expression and possible functions of SATB2 in the nervous system. In mouse embryos, Satb2 expression was detected in the rhombomere region of the hindbrain at E8.5, in the cerebral cortex at E12.5, and in the spinal cord at E15.5. In adult mouse, Satb2 is widely expressed in the cerebral cortex, hippocampus, bed nucleus of the stria terminalis, horizontal limb of the diagonal band, spinal cord, lateral hypothalamic area, arcuate nucleus, hypothalamic paraventricular nucleus, and so on. However, the potential functions of SATB2 in neural development remain yet to be fully elucidated.

In the developing cerebral cortex, Satb2 is expressed in cortical neurons that extend axons across the corpus callosum. The corpus callosum was absent in Satb2−/− mice, and pyramidal neurons extended axons subcortically instead of projecting callosally. CTIP2, a transcription factor that is critical for the extension of subcerebral projections by cortical neurons, was found ectopically expressed in the upper-layer neurons in the absence of Satb2. Mechanistically, Satb2 binds to the upstream promoter region of Ctip2 gene and interacts with histone deacetylase HDAC1 and MTA2 to repress Ctip2 expression. The results indicate that Satb2 is necessary for normal
development of callosal projection neurons by acting as a repressor of CTIP2 (Fig. 2B).

On the other hand, SATB2 is also required for establishing subcerebral projection neuron identity and corticospinal tract (CST) formation.\textsuperscript{19,109} The Forkhead box transcription factors FOXO1 and FOXP2, which are normally expressed in subcerebral projection neurons (SCPN), were lost in Layer 5 and 6 in Satb2\textsuperscript{−/−} mice,\textsuperscript{109} indicating that SATB2 might be important for the differentiation of subcerebral projection neurons. Moreover, the Satb2\textsuperscript{−/−} mice caused a failure of the corticospinal tract (CST) formation.\textsuperscript{109} McKenna et al found that SATB2 directly activated transcription of Fezf2 and Sox5, transcription factors critical for subcerebral neuron development.\textsuperscript{110−115} Furthermore, FEZF2 in turn inhibited high-level SATB2 expression in subcerebral neurons (Fig. 2B).\textsuperscript{19} Thus, these data indicate that the feedback regulatory loop between SATB2 and FEZF2 may be essential for the fate determination of subcerebral projection neurons.

SATB2 may also play a role in intelligence development. In humans, alterations of the SATB2 gene result in developmental delay and intellectual disability.\textsuperscript{39,116,117} The Satb2 mutant mice also displayed manifestations similar to those of human SATB2-mutated patients. Spatial and episodic memory are important cognitive abilities that have been linked to the hippocampus.\textsuperscript{118} SATB2 was detected in the hippocampal CA1 region and activation of hippocampal neuronal activities increased the expression level of SATB2.\textsuperscript{119} Li et al revealed that both of the Satb2\textsuperscript{−/−} mice and the mice conditional knockout the Satb2/C0 mice,\textsuperscript{109} indicating that Satb2/C0 mice result in developmental delay and intellectual disability.\textsuperscript{39} Further, expression of SATB2 in neurons in the parabrachial nucleus is critical for encoding sweet taste.\textsuperscript{122} Taken together, SATB2 plays an essential role in neural development and normal function of the nervous system, although the underlying mechanisms remain to be understood.

### Paradoxical roles of SATB2 in the development and progression of human cancer

Recent studies have demonstrated that SATB2 may play an important role in cancer progression by regulating cell proliferation, apoptosis, metastasis and invasion (Table 1).\textsuperscript{123,124} Here, we briefly review the current findings of SATB2 in the development and/or progression of human cancer.

**SATB2 suppresses the stemness and epithelial-to-mesenchymal transition of cancer stem cells in colorectal cancer**

Colorectal cancer (CRC) is the third most common cancer worldwide, with approximately 600,000 cancer-associated mortalities per year.\textsuperscript{125} Numerous studies have demonstrated that SATB2 is a biomarker for CRC diagnosis and prognosis, as well as a sensitive marker to distinguish CRC from other cancer types.\textsuperscript{41,126,127} SATB2 is highly expressed in the epithelium of the lower gastrointestinal tract.\textsuperscript{126} Wang et al reported that both mRNA and protein levels of SATB2 were significantly reduced in CRC tissue, compared to those in the normal colon tissue samples.\textsuperscript{123} They further demonstrated that low SATB2 levels were associated with tumor invasion and metastasis and poor survival in patients with CRC. In vitro, silencing of Satb2 promoted migration, colony formation, and adhesion of CRC cells, while overexpression of SATB2 repressed migration and proliferation of the CRC cells, as well as their self-renewal ability.\textsuperscript{127} Cancer stem cells represent a small number of cancer cells with stem cell-like properties that can promote tumor-initiating, cancer relapse, and metastasis.\textsuperscript{128,129} Knockdown of SATB2 in colorectal cancer

| Cancer type                          | Expression level of SATB2 compared with normal tissue | High expression of SATB2 | High expression of SATB2 |
|--------------------------------------|------------------------------------------------------|--------------------------|--------------------------|
| Colorectal cancer                    | Lower                                                | Poor prognosis           | Good prognosis           |
| Osteosarcoma                         | Higher                                               | Yes                      |                          |
| Hepatocellular carcinoma             | Higher                                               | Yes                      |                          |
| Breast cancer                        | Higher                                               | Yes                      |                          |
| Head and neck squamous cell carcinoma| Higher                                               | Yes                      |                          |
| Non-small-cell lung carcinoma         | Lower                                                | Yes                      |                          |
| Laryngeal carcinoma                  | Lower                                                | Yes                      |                          |
| Esophageal squamous cell carcinoma   | Lower                                                | Yes                      |                          |
| Ovarian endometrioid carcinoma       | Lower                                                | Yes                      |                          |

**Table 1 Correlation of SATB2 expression with patient survival across different cancer types.**
cells led to an increase in the expression of key cancer stem cell markers, including CD133, CD44, MEIS2, and AXIN2.\textsuperscript{127} Furthermore, SATB2 was shown to affect the expression of the cancer stem cells marker genes by binding to their regulatory elements.\textsuperscript{127} The above-mentioned findings strongly suggest that SATB2 may exhibit an inhibitory function in colorectal cancer progression via downregulation of the stemness of colorectal cancer stem cells by binding to the regulatory elements of certain stem cell markers.

The epithelial-to-mesenchymal transition (EMT), a dynamic process through which epithelial cells acquire mesenchymal features, is crucial for tumor initiation and progression (Fig. 2B).\textsuperscript{130–132} Gu et al. found that the expression of the epithelial marker E-cadherin was decreased in CRC cells when Satb2 was silenced, whereas the mesenchymal markers N-cadherin and vimentin were increased.\textsuperscript{50} Conversely, overexpression of SATB2 in CRC cells resulted in increased expression of E-cadherin and decreased expression of N-cadherin and vimentin. These results indicate that SATB2 may suppress EMT in colorectal cancer. SNAIL is a key transcription factor of EMT and can activate the process of epithelial-to-mesenchymal transition.\textsuperscript{133–135} Wang et al. found that overexpression of SATB2 attenuated the mRNA and protein levels of SNAIL in CRC cells.\textsuperscript{38} Subsequently, they identified three potential SATB2-binding regions within an AT-rich sequence in the Snail promoter and further demonstrated that SATB2 inhibited Snail transcription by recruiting HDAC1 to the Snail promoter (Fig. 2B). Taken together, these results suggest that SATB2 inhibits the progression of colorectal cancer mainly by inhibiting the stemness of cancer stem cells within the tumor and suppressing epithelial-to-mesenchymal transition.

SATB2 promotes the growth and progression of human osteosarcoma

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults with a poor prognosis due to early metastasis and intrinsic therapeutic resistance.\textsuperscript{136} As an important player in bone development, SATB2 has been implicated in osteosarcoma development and progression.\textsuperscript{137–140} SATB2 has been shown to be highly expressed in osteosarcoma and associated with a poorer clinical outcomes (Table 1).\textsuperscript{138,139} Seong et al. established Satb2 knockdown osteosarcoma (OS) cell lines and found that knockdown of Satb2 markedly decreased migration and invasion ability of osteosarcoma (OS) cells.\textsuperscript{138} Gene expression profiling analysis of the Satb2 knockdown OS cells identified that the actin-binding protein, epithelial protein lost in neoplasm (EPLIN), is one of the most unregulated genes in Satb2 knockdown OS cells.\textsuperscript{138} Down-regulation of the expression of EPLIN partially rescued the inhibited invasion phenotype in Satb2 knockdown OS cells.\textsuperscript{138} These findings indicate that SATB2 may modulate the invasion phenotype of OS, partially mediated by affecting EPLIN. It has also been reported that N-cadherin is an essential target gene of SATB2, and that SATB2 promotes osteosarcoma growth via the N-cadherin/NF-kB pathway.\textsuperscript{139} These results suggest that SATB2 plays an important role in osteosarcoma progression and is a potential target for future treatments.

SATB2 as a prognostic marker for many types of human cancer

Increased expression of SATB2 has been shown in hepatocellular carcinoma tissue compared to that in normal liver tissues and SATB2 promotes the epithelial–mesenchymal transition in hepatocellular carcinoma cells (Table 1).\textsuperscript{40,141,142} It has also been reported that miR-34a and miR211 inhibits hepatocellular carcinoma progression by downregulating SATB2.\textsuperscript{40,142} Regarding breast cancer, SATB2 induces normal human breast mammary epithelial cells to transform into progenitor-like cells leading to a malignant phenotype. The high expression of SATB2 is correlated with shorter overall survival in breast cancer.\textsuperscript{143,144} Furthermore, SATB2 enhanced chemoresistance of head and neck squamous cell carcinoma, and higher expression of SATB2 showed a significant association with poorer prognosis.\textsuperscript{145}

On the contrary, the expression of SATB2 was found to be decreased in non-small-cell lung carcinoma, and the downregulation of SATB2 was related to poor prognosis.\textsuperscript{146–148} Furthermore, silencing SATB2 in non-small-cell lung carcinoma cells induced EMT by upregulating EMT-inducing transcription factors including Slug, Twist, and Zeb1.\textsuperscript{147} In laryngeal carcinoma, esophageal squamous cell carcinoma, and ovarian endometrioid carcinoma, the expression of SATB2 protein in carcinoma tissues was much lower than that in paracarcinoma tissues. As expected, the overall survival rate of patients with high SATB2 expression was higher than those with low SATB2 expression in these cancers.\textsuperscript{149–151}

Taken together, these results indicate that the expression of SATB2 and the correlation of SATB2 expression with patient survival vary significantly across cancer types as summarized in Table 1, suggesting that SATB2 may play complex roles in cancer development and progression, and its functions may be cell- or context-dependent. Thus, more research is required to gain a better understanding of the molecular mechanisms of SATB2 in tumorigenesis.

Potential applications of SATB2 in regenerative medicine

Given the fact that SATB2 plays an important role in regulating osteoblast differentiation and skeletogenesis, it is conceivable that SATB2 may be used as a promising osteogenic factor for bone regeneration (Fig. 3). Titanium implants are widely used for restoring missing teeth in dental clinics. Osseointegration, also called direct bone-to-implant contact (BIC), is achieved by the bone regeneration around the implant and plays a key role in successful dental implants.\textsuperscript{152,153} Yan et al. investigated the function of SATB2 in promoting osseointegration of dental implants in a mouse model.\textsuperscript{154} The retroviral vectors (pBABE-Satb2 and pBABE-hygro) were locally applied to the bone defects on the femurs of mice, and then the implants were placed. Three weeks after implantation, local application of SATB2 augmented new bone formation around the implants and
promoted osseointegration on the bone-implant interface by upregulating the expression of osteogenic transcription factors and bone matrix proteins.\textsuperscript{151} Another study from the same group used pBABE-Satb2 retroviral vector to transduced bone marrow mesenchymal stem cells (BMSCs), and then administered the BMSCs to the bone defects in the mouse femurs prior to titanium implant placement.\textsuperscript{155} They found that overexpression of SATB2 in BMSCs significantly enhanced osseointegration of dental implants. These findings demonstrated that SATB2 effectively enhanced the osseointegration of dental implants.

Bone defects are a common and frequent disease in the clinic, and the major goal of bone defects treatment is bone regeneration. Ye et al demonstrated the potency of SATB2 to repair calvarial defects in nude mice.\textsuperscript{156} In their studies, induced pluripotent stem cells (iPSCs) were transduced with SATB2 overexpressing plasmid (pBABE-hygro-Satb2) and they found that the mRNA levels of several key osteogenic genes, including Osx, Runx2, Bsp and Ocn, were increased in Satb2-transduced iPSCs while the levels of Hoxa2, which inhibits osteogenic differentiation were decreased.\textsuperscript{157} The Satb2-transduced iPSCs and control iPSCs were seeded onto a silk scaffold and then transplanted into the surgically induced calvarial defects in nude mice. Five weeks after transplantation, both micro-computed tomography and histological analysis revealed that the group that received Satb2-transduced iPSCs in silk scaffolds had better regeneration of new bones in the calvarial defects compared to that in the control group.\textsuperscript{156}

Another compelling study demonstrated the clinical applicability of SATB2 in the repair of alveolar bone defects. Zhang et al found that transduction of adult stem cells (dental follicle cells and bone marrow stromal cells) with Satb2 retroviral vectors promoted osteogenic differentiation and angiogenic activity \textit{in vitro}.\textsuperscript{77} They further showed that more transplanted cells underwent osteogenic differentiation in the Satb2-overexpressing group than those of the control group, and new bone formation in alveolar bone defects was consequently accelerated in the Satb2-overexpressing groups.\textsuperscript{77} These results provide promise of SATB2 induction and stem cell transplantation as a therapeutic strategy to repair bone defects.

In addition to repairing bone defects, SATB2 has also been shown to be effective in preventing alveolar bone loss in the ovariectomized rat model.\textsuperscript{157,158} The alveolar bone of ovariectomized rats displayed decreased bone volume, sparser trabecular bone, and fewer osteoblasts compared to those of the sham-controlled group.\textsuperscript{158} Moreover, BMSCs originated from the alveolar bone of ovariectomized rats displayed senescent phenotypes such as low proliferation, diminished stemness and osteogenic capacity.\textsuperscript{158} However, overexpression of SATB2 could rejuvenate these senescent BMSCs from O VX rats, and systemic injection of SATB2-overexpressing BMSCs into ovariectomized rats markedly attenuated alveolar bone loss.\textsuperscript{158} These results not only demonstrate the potential of the clinical application of SATB2, but also the promise of using BMSCs in preventing alveolar bone loss.

**Conclusion and future directions**

SATB2 is a nuclear matrix protein that orchestrates many aspects of physiological and pathological processes by regulating gene transcription. As a molecular node in a transcriptional network regulating osteoblast differentiation, SATB2 plays a crucial role in craniofacial pattern and skeletogenesis. Increasing evidence has demonstrated that SATB2 is an effective osteogenic factor and may be utilized as a regenerative agent in osseous defects. In addition to the osteoinductive properties, SATB2 also has implications for neural development and cancer progression. Thus, SATB2 may be explored as a potential diagnostic and/or prognostic biomarker for the clinical management of neural disorders and cancer. However, the molecular mechanisms through which SATB2 functions in osteogenesis and other biological processes remain unclear and warrant further investigation to explore the potential of SATB2 in clinical treatment.

**Conflict of interests**

The authors declare no competing conflict of interest.

**Acknowledgements**

This reported work was supported in part by research grants from the National Natural Science Foundation of China (No. #81870758 to HZ), Chongqing Research Program of Basic Research and Frontier Technology (No. #cstc2017jcyjAX0020 to HZ).

**References**

1. Bueno EM, Glowacki J. Cell-free and cell-based approaches for bone regeneration. \textit{Nat Rev Rheumatol}. 2009;5(12):685–697.
2. Kneser U, Schaefer DJ, Polykandriotis E, Horch RE. Tissue engineering of bone: the reconstructive surgeon’s point of view. \textit{J Cell Mol Med}. 2006;10(1):7–19.
3. Galande S, Purbev PK, Notani D, Kumar PP. The third dimension of gene regulation: organization of dynamic chromatin...
loopscape by SATB1. *Curr Opin Genet Dev.* 2007;17(5):408–414.

4. Dobreva G, Dambacher J, Grosschedl R. SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. *Genes Dev.* 2003;17(24):3048–3061.

5. Pavan Kumar P, Purbyte PK, Sinha CK, et al. Phosphorylation of SATB1, a global gene regulator, acts as a molecular switch regulating its transcriptional activity in vivo. *Mol Cell.* 2006;22(2):231–243.

6. FitzPatrick DR, Carr IM, McLaren L, et al. Identification of SATB2 as the cleft palate gene on 2q32-q33. *Huge: a database for human large proteins identified in the nuclear matrix.* 2007;28(1):331–332.

7. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. *Nature.* 2002;419(6907):641–645.

8. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. *Nat Genet.* 2003;34(1):42–51.

9. Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. *Nat Genet.* 2006;38(11):1278–1285.

10. Kumar PP, Bischof O, Purbyte PK, et al. Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus. *Nat Cell Biol.* 2007;9(1):45–56.

11. Kikuno R, Nagase T, Suyama M, Waki M, Hirosawa M, Ohara O. SATB1 targets chromatin remodelling to regulate genes over long distances. *Nature.* 2002;419(6907):641–645.

12. Dickinson LA, Dickinson CD, Kohwi-Shigematsu T. An atypical homeodomain in SATB1 promotes specific recognition of the key structural element in a matrix attachment region. *J Biol Chem.* 1997;272(17):11463–11470.

13. Yamasaki K, Akiba T, Yamasaki T, Harata K. Structural basis for recognition of the matrix attachment region of DNA by transcription factor SATB1. *Nucleic Acids Res.* 2007;35(15):5073–5084.

14. Bereznay R, Coffey DS. Identification of a nuclear protein matrix. *Biochem Biophys Res Commun.* 1974;60(4):1410–1417.

15. Mirkovitch J, Mirault ME, Laemmli UK. Organization of the higher-order chromatin loop: specific DNA attachment sites on nuclear scaffold. *Cell.* 1984;39(1):223–232.

16. Cockerill PN, Garrard WT. Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sites. *Cell.* 1986;44(2):273–282.

17. Gyorgy AB, Szemes M, de Juan Romero C, Tarabykin V, Agoston DV. SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons. *Eur J Neurosci.* 2008;27(8):865–873.

18. Dobreva G, Chahrouf M, Dautzenberg M, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. *Cell.* 2006;125(5):971–986.

19. McKenna WL, Ortiz-Londono CF, Mathew TK, Hoang K, Katzman S, Chen B. Mutual regulation between Satb2 and Fezf2 in the developing cerebellum. *Proc Natl Acad Sci U S A.* 2015;112(37):11702–11707.

20. Xu M, Xu X, Pan B, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. *Mol Cancer.* 2019;18(1):15.

21. Yan S, Zhang R, Ke W, et al. Characterization of the essential role of Bone Morphogenetic Protein 9 (BMP9) in osteogenic differentiation of mesenchymal stem cells (MSCs) through RNA interference. *Genes Dis.* 2018;5(2):172–184.

22. Zhao C, Jiang W, Zhou N, et al. Sox9 augments BMP2-induced chondrogenic differentiation by downregulating Smad7 in mesenchymal stem cells (MSCs). *Genes Dis.* 2017;4(4):229–239.

23. Zhang F, Song J, Zhang H, et al. Wnt and BMP signaling crosstalk in regulating dental stem cells: implications in dental tissue engineering. *Genes Dis.* 2016;3(4):263–276.

24. Capuruto LC, Anhe GF, Cambiaggi TD, et al. Modulation of bone morphogenetic protein-9 expression and processing by insulin, glucose, and glucocorticoids: possible candidate for hepatic insulin-sensitizing substance. *Endocrinology.* 2008;149(12):6326–6335.

25. Kim J, Kim M, Jeong Y, et al. BMP9 induces cord blood-derived endothelial progenitor cell differentiation and ischemic neovascularization via ALK1. *Arterioscler Thromb Vasc Biol.* 2015;35(9):2020–2031.

26. Franco CA, Gerhardt H. Blood flow boosts BMP signaling to keep vessels in shape. *J Cell Biol.* 2016;214(7):793–795.

27. Xu DJ, Zhao YZ, Wang J, He JW, Weng YG, Luo JY. Smads, p38 and ERK1/2 are involved in BMP9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells. *BMB reports.* 2012;45(4):247–252.

28. Bonilla-Claudio M, Wang J, Bai Y, Klysik E, Selever J, Martin JF. BMP signaling regulates a dose-dependent transcriptional program to control facial skeletal development. *Development.* 2012;139(4):709–719.

29. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. *Cell.* 2002;108(1):17–29.

30. Tang W, Li Y, Osimiri L, Zhang C. Osteoblast-specific transcription factor Osterix (OxS) is an upstream regulator of Satb2 during bone formation. *J Biol Chem.* 2011;286(38):32995–33002.

31. Apostolova G, Loy B, Dorn R, Dechant G. The sympathetic neurotransmitter switch depends on the nuclear matrix protein Satb2. *J Neurosci.* 2010;30(48):16356–16364.

32. Zhao X. SUMO-mediated regulation of nuclear functions and signaling processes. *Mol Cell.* 2018;71(3):409–418.

33. Matsui M, Corey DR. Non-coding RNAs as drug targets. *Nat Rev Drug Discov.* 2017;16(3):167–179.

34. Anastasiadou E, Jacobs LS, Slack FJ. Non-coding RNA networks in cancer. *Nat Rev Cancer.* 2018;18(1):5–18.

35. Ling H, Fabrini M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov.* 2013;12(11):847–865.

36. Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet.* 2019;20(11):675–691.

37. Atkinson SR, Marguerat S, Bahler J. Exploring long non-coding RNAs through sequencing. *Semin Cell Dev Biol.* 2012;23(2):200–205.

38. Wang YQ, Jiang DM, Hu SS, et al. SATB2-AS1 suppresses colorectal carcinoma aggressiveness by inhibiting SATB2-dependent snail transcription and epithelial-mesenchymal transition. *Cancer Res.* 2019;79(14):3542–3556.

39. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer.* 2006;6(4):259–269.

40. Jiang G, Cui Y, Yu X, Wu Z, Ding G, Cao L. miR-211 suppresses osteoblast differentiation and invasion in colorectal cancer by targeting SATB2. *Mol Cell Biol.* 2018;38(2):9466.

41. Jiang G, Cui Y, Yu X, Wu Z, Ding G, Cao L. miR-211 suppresses osteoblast differentiation and invasion in colorectal cancer by targeting SATB2. *Mol Cell Biol.* 2018;38(2):9466.

42. Jiang G, Cui Y, Yu X, Wu Z, Ding G, Cao L. miR-211 suppresses osteoblast differentiation and invasion in colorectal cancer by targeting SATB2. *Mol Cell Biol.* 2018;38(2):9466.

43. Jiang G, Cui Y, Yu X, Wu Z, Ding G, Cao L. miR-211 suppresses osteoblast differentiation and invasion in colorectal cancer by targeting SATB2. *Mol Cell Biol.* 2018;38(2):9466.
The physiological and pathological roles of SATB2

44. Tang J, Zhang Z, Jin X, Shi H. miR-383 negatively regulates osteoblastic differentiation of bone marrow mesenchymal stem cells in rats by targeting Satb2. Bone. 2018;114:137–143.

45. Li JY, Wei X, Sun Q, et al. MicroRNA-449b-5p promotes the progression of osteoporosis by inhibiting osteogenic differentiation of BMSCs via targeting Satb2. Eur Rev Med Pharmacol Sci. 2019;23(15):6394–6403.

46. Shen H, Lu C, Shi J, Li H, Si J, Shen G. Satb2 expression in Foxc1-promoted osteogenic differentiation of MC3T3-E1 cells is negatively regulated by microRNA-103-3p. Acta Biochim Biophys Sin. 2019;51(6):588–597.

47. Wei J, Shi Y, Zheng L, et al. miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol. 2012;197(4):509–521.

48. Ge J, Guo S, Fu Y, et al. Dental follicle cells participate in tooth eruption via the RUNX2-MIR-31-SATB2 loop. J Dent Res. 2015;94(7):936–944.

49. Aprelikova O, Yu X, Palla J, et al. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle. 2010;9(21):4387–4398.

50. Gu J, Wang G. SATB2 targeted by methylated miR-34c-5p suppresses proliferation, migration and metastasis attenuating the epithelial-mesenchymal transition in colorectal cancer. Cell Prolif. 2018;51(4):e12455.

51. Xu L, Fu Y, Zhu W, et al. microRNA-31 inhibition partially ameliorates the deficiency of bone marrow stromal cells from cleidocranial dysplasia. J Cell Biochem. 2019;120(6):9472–9486.

52. Yu L, Xu Y, Qu H, Yu Y, Li W, Zhao Y. Decrease of MiR-31 induced by TNF-α inhibitor activates SATB2/RUNK2 pathway and promotes osteogenic differentiation in ethanol-induced osteonecrosis. J Cell Physiol. 2019;234(4):4314–4326.

53. Hunt P, Krumlauf R. Deciphering the Hox code: clues to patterning branchial regions of the head. Cell. 1991;66(6):1075–1078.

54. Bronner-Fraser M. Neural crest cell migration in the developing embryo. Trends Cell Biol. 1993;3(11):392–397.

55. Kostges G, Lumsden A. Rhombencephalic neural crest subdivisions by Dlx genes. Development. 1996;122(10):3229.

56. Britanova O, Depew MJ, Schwark M, et al. Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss of function is required for craniofacial and limb abnormalities. Genes Dev. 1998;12(17):2735–2747.

57. Zarate YA, Bosanko KA, Caffrey AR, et al. Mutation update for syndrome exhibiting multiple odontomas. Am J Med Genet. 2006;192e:1029–1032.

58. Zarate YA, Boscari K, Caffrey AR, et al. Mutation update for the SATB2 gene. Hum Mutat. 2019;40(8):1013–1029.

59. Zarae YA, Fish JL. SATB2-associated syndrome: mechanisms, phenotype, and practical recommendations. Am J Med Genet. 2017;173(2):327–337.

60. Scott J, Adams C, Beestra S, Zarae YA. SATB2-associated syndrome (SAS) and associated dental findings. Spec Care Dent. 2019;39(2):220–224.

61. Kikuchi T, Mishima H. Patients with SATB2-associated syndrome exhibiting multiple odontomas. Am J Med Genet. 2018;176(12):2614–2622.

62. Zhao Y, Guo YJ, Tomac AC, et al. Isolated cleft palate in mice with a targeted mutation of the Lihm homeobox gene lhx8. Proc Natl Acad Sci U S A. 1999;96(26):15002–15006.

63. van den Boogaard MJ, Dorland M, Beemer FA, van Amstel HK. MSX1 mutation is associated with orofacial clefting and tooth agenesis in humans. Nat Genet. 2000;24(4):342–343.

64. Liang J, Von dent Hoff J, Lange J, Ren Y, Bian Z, Carels CE. MSX1 mutations and associated disease phenotypes: genotype-phenotype relations. Eur J Hum Genet. 2016;24(12):1663–1670.

65. Jezewski PA, Vieira AR, Nishimura C, et al. Complete sequencing shows a role for MSX1 in non-syndromic cleft lip and palate. J Med Genet. 2003;40(6):399–407.

66. Schuffenhauer S, Leifheit HJ, Lichtner P, Peters H, Murken J, Emmerich P. De novo deletion (14)(q11.2q13) including PAX9: clinical and molecular findings. J Med Genet. 1999;36(3):233–236.

67. Peters H, Neubuser A, Katochkwil B, Bailing R. Pax9-deficient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev. 1998;12(17):2735–2747.

68. Beverdam A, Brouwer A, Reijnen M, Korving J, Meijlink F. Severe nasal clefting and abnormal embryonic apoptosis in Alx3/Alx4 double mutant mice. Development. 2001;128(20):3975–3986.

69. Park JW, Cai J, McIntosh I, et al. High throughput SNP and expression analyses of candidate genes for non-syndromic oral clefts. J Med Genet. 2006;43(7):598–608.

70. Li C, Lan Y, Krumlauf R, Jiang R. Modulating Wnt signaling rescues palate morphogenesis in Pax9 mutant mice. J Dent Res. 2017;96(11):1273–1281.

71. Yagnik G, Ghuman A, Kim S, et al. ALX4 gain-of-function mutations in nonsyndromic craniosynostosis. Hum Mutat. 2012;33(12):1626–1629.

72. Jia S, Zhou J, Fanelli C, et al. Small-molecule Wnt agonists correct cleft palates in Pax9 mutant mice in utero. Development. 2017;144(20):3819–3828.

73. Satokata I, Maas R. Msx1 deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nat Genet. 1994;6(4):348–356.

74. Kim IS, Jeong SJ, Kim SH, Jung JH, Park YG, Kim SH. Special AT-rich sequence-binding protein 2 and its related genes play key roles in the differentiation of MC3T3-E1 osteoblast like cells. Biochem Biophys Res Commun. 2019;417(2):697–703.

75. Ellis DL, Krumlauf R. Bone formation: the nuclear matrix reloaded. Cell. 2006;125(5):840–842.

76. Zhang J, Tu Q, Grosschedl R, et al. Roles of SATB2 in osteogenic differentiation and bone regeneration. Tissue Eng. 2011;17(13–14):1767–1776.

77. Kanzler B, Kuschert SJ, Liu YH, Mallo M. Hexa-2 restricts the chondrogenic domain and inhibits bone formation during development of the branchial area. Development. 1998;125(14):2587–2597.

78. Trainor PA, Krumlauf R. Hox genes, neural crest cells and branchial arch patterning. Curr Opin Cell Biol. 2001;13(6):698–705.

79. Frasch M, Chen X, Lufkin T. Evolutionary-conserved enhancers direct region-specific expression of the murine Hoxa-1 and Hoxa-2 loci in both mice and Drosophila. Development. 1995;121(4):957–974.

80. Lampe X, Picard JJ, Rezsohazy R, The Hoxa2 enhancer 2 directs MSX1 expression in the branchial arches and their roles in hematopoiesis, osteogenesis, and leukemia. J Cell Biochem. 2019;Suppl 32–33:51–58.
85. Mevel R, Draper JE. RUNX transcription factors: orchestrators of development. Development. 2019;146(17):dev148296.
86. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfα1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89(5):755–764.
87. Kim IS, Otto F, Zabel B, Mundlos S. Regulation of chondrocyte differentiation by Cbfα1. Mech Dev. 1999;80(2):159–170.
88. Takeda S, Bonnamy JP, Owen MJ, Ducy P, Karsenty G. Continuous expression of Cbfα1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfα1-deficient mice. Genes Dev. 2001;15(4):467–481.
89. Inada M, Yasui T, Nomura S, et al. Maturational disturbance of chondrocytes in Cbfα1-deficient mice. Dev Dynam. 1999;214(4):279–290.
90. Deng Y, Zhou H, Zou D, et al. The role of miR-31-modified adipose tissue-derived stem cells in repairing rat critical-sized calvarial defects. Biomaterials. 2013;34(28):6717–6728.
91. Yang X, Matsuda K, Bialek P, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 2004;117(3):387–398.
92. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. J Biol Chem. 2007;282(28):17040–17050.
93. Yoshizawa T, Hinoi E, Jung DY, et al. The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest. 2009;119(9):2807–2817.
94. Yang X, Karsenty G. ATF4, the osteoblast-specific gene expression in non-osteoblastic cells. J Biol Chem. 2004;279(45):47109–47114.
95. Holm E, Aubin JE, Hunter GK, Bierer F, Goldberg HA. Loss of bone sialoprotein leads to impaired endochondral bone development and mineralization. Bone. 2015;71:145–154.
96. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA. Bone sialoprotein expression enhances osteoblastic differentiation and matrix mineralization in vitro. Bone. 2007;41(3):462–473.
97. Weirnb M, Shinar D, Rodan GA. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res. 1990;5(8):831–842.
98. Derkx P, Nigg AL, Bosman FT, et al. Immunolocalization and quantification of noncollagenous bone matrix proteins in methylymethacrylate-embedded adult human bone in combination with histomorphometry. Bone. 1998;22(4):367–373.
99. Tsao YT, Huang YJ, Wu HH, Liu YA, Liu YS, Lee OK. Osteocalcin mediates bimaterialization during osteogenic maturation in human mesenchymal stromal cells. Int J Mol Sci. 2017;18(1):159.
100. Bidwell JP, Van Wijnen AJ, Fey EG, et al. Osteocalcin gene promoter-binding factors are tissue-specific nuclear matrix components. Proc Natl Acad Sci U S A. 1993;90(8):3162–3166.
101. Ducy P, Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol. 1995;15(4):1858–1869.
102. Alcamo EA, Chirivella L, Dautzenberg M, et al. Satb2 regulates callosal projection neuron identity in the developing cerebral cortex. Neuron. 2008;57(3):364–377.
103. Britanova O, de Juan Romero C, Cheung A, et al. Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex. Neuron. 2008;57(3):378–392.
104. Leone DP, Srinivasan K, Chen B, Alcamo E, McConnell SK. The determination of projection neuron identity in the developing cerebral cortex. Curr Opin Neurobiol. 2008;18(1):28–35.
105. Kwan KY, Sestan N, Anton ES. Transcriptional co-regulation of neuronal migration and laminar identity in the neocortex. Development. 2012;139(9):1535–1546.
106. Huang Y, Song NN, Lan W, et al. Expression of transcription factor Satb2 in adult mouse brain. Anat Rec. 2013;296(3):452–461.
107. Arlotta P, Molyneaux BJ, Chen J, Inoue J, Kominami R, Macklis JD. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. Neuron. 2005;45(2):207–221.
108. Baranek C, Dittrich M, Parthasarathy S, et al. Protooncogene Ski cooperates with the chromatin-remodeling factor Satb2 in specifying callosal neurons. Proc Natl Acad Sci U S A. 2012;109(9):3546–3551.
109. Leone DP, Heavner WE, Ferenczi EA, et al. Satb2 regulates the differentiation of both callosal and subcortical projection neurons in the developing cerebral cortex. Cerebr Cortex. 2015;25(10):3406–3419.
110. Molyneaux BJ, Arlotta P, Hirata T, Hibi M, Macklis JD. Fez1 is required for the birth and specification of corticospinal motor neurons. Neuron. 2005;47(6):817–831.
111. Chen B, Schaevitz LR, McConnell SK. Fez1 regulates the differentiation and axon targeting of layer 5 subcortical projection neurons in cerebral cortex. Proc Natl Acad Sci U S A. 2005;102(47):17184–17189.
112. Chen B, Wang SS, Hatton AM, Rayburn H, Nelson SB, McConnell SK. The Fez2-Ctip2 genetic pathway regulates the fate choice of subcortical projection neurons in the developing cerebral cortex. Proc Natl Acad Sci U S A. 2008;105(32):11382–11387.
113. McKenna WL, Betancourt J, Larkin KA, et al. Tbr1 and Fez2 regulate alternate corticofugal neuronal identities during neocortical development. J Neurosci. 2011;31(2):549–564.
114. Kwan KY, Lam MM, Krsnik Z, Kawasawa YI, Lefebvre V, Sestan N. SOX5 postmitotically regulates migration, post-migratory differentiation, and projections of subplate and deep-layer neocortical neurons. Proc Natl Acad Sci U S A. 2008;105(41):16021–16026.
115. Lai T, Jabadou D, Molyneaux BJ, et al. SOX5 controls the sequential generation of distinct corticofugal neuron subtypes. Neuron. 2008;57(2):232–247.
116. Docker D, Schubach M, Menzel M, et al. Further delineation of the SATB2 phenotype. Eur J Hum Genet. 2014;22(8):1034–1039.
117. Zarate YA, Perry H, Ben-Omran T, et al. Further supporting evidence for the SATB2-associated syndrome found through whole exome sequencing. Am J Med Genet A. 2015;167A(5):1026–1032.
118. Burgess N, Maguire EA, O’Keefe J. The human hippocampus and spatial and episodic memory. Neuro. 2002;35(4):625–641.
119. Li Y, You QL, Zhang SR, et al. Satb2 ablation impairs hippocampus-based long-term spatial memory and short-term working memory and immediate early genes (IEGs)-Mediated hippocampal synaptic plasticity. Mol Neurobiol. 2017.
120. Jaitner C, Reddy C, Abentung A, Whittle N, Rieder D, Delekate A. Satb2 determines miRNA expression and long-term memory in the adult central nervous system. Neuron. 2016;5:e17361.
121. Okuno H. Regulation and function of immediate-early genes in the brain: beyond neuronal activity markers. Neurosci Res. 2011;69(3):175–186.
122. Fu O, Iwai Y, Kondoh K, Misaka T, Minokoshi Y, Nakajima KI. Satb2-Expressing neurons in the parabrachial nucleus encode sweet taste. Cell Rep. 2019;27(6):1650–1656.
123. Wang S, Zhou J, Wang XY, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219(1):114–122.
124. Guo C, Xiong D, Yao X, et al. Decreased SATB2 expression is associated with metastasis and poor prognosis in human clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(4):3710–3718.

125. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502.

126. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35(7):937–948.

127. Li Y, Liu YH, Hu YY, Chen L, Li JM. Special AT-rich sequence-binding protein 2 acts as a negative regulator of stemness in colorectal cancer cells. World J Gastroenterol. 2016;22(38):8528–8539.

128. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010–1012.

129. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–5828.

130. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–292.

131. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629.

132. Krebs AM, Mitschke J, Lasierra Losada M, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol. 2017;19(5):518–529.

133. Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology. 2013;63(1):36–49.

134. Yu W, Roy SK, Ma Y, LaVeist TA, Shankar S, Srivastava RK. Higher expression of SATB2 in hepatocellular carcinoma of African Americans determines more aggressive phenotypes than those of Caucasian Americans. J Cell Mol Med. 2019;23(12):7999–8009.

135. Wu G, Li Z, Wang Y, Ju X, Huang R. miR-34a inhibits cell proliferation by targeting SATB2 in hepatocellular carcinoma. BioMed Res Int. 2018;2018:2863902.

136. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009;9:18.

137. Seong BK, Lau J, Cheng LS, et al. SATB2 augments DeltaN-p63alpha in head and neck squamous cell carcinoma. EMBO Rep. 2010;11(10):777–783.

138. Davis JL, Horvai AE. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for colorectal cancer. J Cell Physiol. 2011;226:263–270.

139. Yu W, Ma Y, Ochoa AC, Shankar S, Srivastava RK. Cellular transformation of human mammary epithelial cells by SATB2. Stem Cell Res. 2017;19:139–147.

140. Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology. 2013;63(1):36–49.

141. Yu W, Lau J, Cheng LS, et al. SATB2 augments DeltaN-p63alpha in head and neck squamous cell carcinoma. EMBO Rep. 2010;11(10):777–783.

142. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15(9):1010–1012.

143. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009;9:18.

144. Wu G, Li Z, Wang Y, Ju X, Huang R. miR-34a inhibits cell proliferation by targeting SATB2 in hepatocellular carcinoma. BioMed Res Int. 2018;2018:2863902.

145. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009;9:18.

146. Ma YN, Zhang HY, Fei LR, et al. SATB2 suppresses non-small cell lung cancer invasiveness by G9a. Clin Exp Med. 2018;18(1):37–44.

147. Kucuksayan H, Ozes ON, Akca H. Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells. Lung Canc. 2016;98:122–129.

148. Kucuksayan H, Akca H. The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells. Tumour Biol. 2017;39(9):2010428317706212.

149. Liu TR, Xu LH, Yang AK, et al. Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. PLoS One. 2012;7(7):e40704.

150. Geng GJ, Li N, Mi YJ, et al. Prognostic value of SATB2 expression in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):423–431.

151. Le Page C, Köbel M. A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. J Pathol Clin Res. 2019;5(3):177–188.

152. Schneider GB, Zaharias R, Seabold D, Keller J, Stanford C. Differentiation of preosteoblasts is affected by implant surface microtopographies. J Biomed Mater Res. 2004;69(3):462–468.

153. Linder L, Albrektsson T, Branemark PI, et al. Electron microscopic analysis of the bone-titanium interface. Acta Orthop Scand. 1983;54(1):45–52.

154. Yan SG, Zhang J, Tu QS, et al. Enhanced osseointegration of titanium implant through the local delivery of transcription factor SATB2. Biomaterials. 2011;32(33):8676–8683.

155. Yan SG, Zhang J, Tu Q, et al. Transcription factor and bone marrow stromal cells in osseointegration of dental implants. Eur Cell Mater. 2013;26:263–270.

156. Ye JH, Xu YJ, Gao J, et al. Critical-size calvarial bone defects healing in a mouse model with silk scaffolds and SATB2-modified iPSCs. Biomaterials. 2011;32(22):5065–5076.

157. Wu G, Xu R, Zhang P, et al. Estrogen regulates stemness and senescence of bone marrow stromal cells to prevent osteoporosis via ER(II)-SATB2 pathway. J Cell Physiol. 2018;233(5):4194–4204.

158. Xu R, Fu Z, Liu X, et al. Transplantation of osteoporotic bone marrow stromal cells rejuvenated by the overexpression of SATB2 prevents alveolar bone loss in ovariectomized rats. Exp Gerontol. 2016;84:71–79.